Product nameAnti-Cytokeratin 10 antibody
See all Cytokeratin 10 primary antibodies
DescriptionRabbit polyclonal to Cytokeratin 10
Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
Species reactivityReacts with: Rat, Human
Synthetic peptide corresponding to Human Cytokeratin 10 aa 550 to the C-terminus (C terminal) conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in Human Skin tissue lysate and in human skin FFPE tissue sections This antibody gave a positive result when used in the following formaldehyde/methanol fixed cell lines: MCF-7
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab111447 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 62 kDa (predicted molecular weight: 59 kDa).|
|IHC-P||Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
Tissue specificitySeen in all suprabasal cell layers including stratum corneum.
Involvement in diseaseDefects in KRT10 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
Defects in KRT10 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
Sequence similaritiesBelongs to the intermediate filament family.
- Information by UniProt
- BCIE antibody
- BIE antibody
- CK 10 antibody
IHC image of Cytokeratin 10 staining in human skin melanoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab111447, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
ab111447 stained MCF-7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab111447 at 5µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Anti-Cytokeratin 10 antibody (ab111447) at 1 µg/ml + Human skin tissue lysate - total protein (ab30166) at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 59 kDa
Observed band size: 62 kDa why is the actual band size different from the predicted?
Exposure time: 16 minutes
IHC-P image of Cytokeratin 10 staining using human skin using ab111447 (1:6000). The sections were subjected to heat mediated antigen retrieval using citric acid pH 6. The sections were blocked using 1% BSA for 10 mins at 21°C. ab111447 was incubated for 2 hours at 21°C. The secondary antibody used was Goat polyclonal to Rabbit IgG conjugated to biotin (1:250).
IHC-P image of Cytokeratin 10 staining using rat E18 skin using ab111447 (1:5000). The sections were subjected to heat mediated antigen retrieval using citric acid pH 6. The sections were blocked using 1% BSA for 10 mins at 21°C. ab111447 was incubated for 2 hours at 21°C. The secondary antibody used was Goat polyclonal to Rabbit IgG conjugated to biotin (1:250).
This product has been referenced in:
- Deng X et al. Development of a Porcine Full-Thickness Burn Hypertrophic Scar Model and Investigation of the Effects of Shikonin on Hypertrophic Scar Remediation. Front Pharmacol 9:590 (2018). Read more (PubMed: 29922164) »
- Yang S et al. Abnormalities in the basement membrane structure promote basal keratinocytes in the epidermis of hypertrophic scars to adopt a proliferative phenotype. Int J Mol Med 37:1263-73 (2016). IHC-P, WB ; Human . Read more (PubMed: 26986690) »